Pfizer stock up 1.2% premarket after drugmaker announces positive results from Phase 4 eczema study
Shares of Pfizer Inc. ticked up 1.2% in premarket trade Monday after the drugmaker said a Phase 4 study showed that an eczema treatment was well-tolerated in babies between 3 months and two years of age when used over a period of four weeks. The treatment, a crisaborole ointment that is steroid-free, is currently approved in the U.S. to treat eczema in children two years of age and older. The company said a detailed analysis of the study would be presented later at a scientific meeting. Shares of Pfizer have gained 19.4% in the past 12 months, while the S&P 500 has gained 8.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.